Cytokinetics
The Director, Strategy & Business Development is a hands-on strategic leader who drives critical analytical and strategic work across Cytokinetics, shaping enterprise planning and informing business development decisions. The role leads the company's AI ambition as a strategic initiative while supporting the Business Development team with drug revenue forecasting and valuation models. This position requires a professional comfortable with building financial models, framing strategy narratives, and developing AI tools.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
1998
Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of pioneering scientific innovation in muscle biology, focused on developing medicines for patients with diseases of cardiac muscle dysfunction, including heart failure and hypertrophic cardiomyopathy (HCM). Building on its leadership in muscle biology, the company advances a pipeline of small molecule muscle activators and inhibitors, and received its first FDA approval in 2025 for a cardiac myosin inhibitor. Cytokinetics is also engaged in neuromuscular disease research and is committed to improving the healthspan of people living with debilitating conditions of impaired muscle function.
Leerink Maintains Outperform for Cytokinetics, Incorporated (CYTK) March 2026
1 day ago
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Nov 10, 2025
Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK
5 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Cytokinetics.
38% above the average for this role
Why Cytokinetics (CYTK) Is a Buy
2 weeks ago